This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jenkins, R. B. Articles by Buckner, J. C. Search for Related Content PubMed PubMed Citation Articles by Jenkins, R. B. Articles by Buckner, J. C.

A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma

¹ Mayo Clinic, Rochester, Minnesota; ² Merit Care Community Clinical Oncology Program, Fargo, North Dakota; and ³ Wake Forest University School of Medicine, Winston-Salem, North Carolina

Requests for reprints: Robert B. Jenkins, Division of Laboratory Genetics, Mayo College of Medicine, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-9617; Fax: 507-284-0043; E-mail: rjenkins{at}mayo.edu.

Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma. The deletions usually involve whole chromosome arms, suggesting a t(1;19)(q10;p10). Using stem cell medium, we cultured a few tumors. Paraffin-embedded tissue was obtained from 21 Mayo Clinic patients and 98 patients enrolled in 2 North Central Cancer Treatment Group (NCCTG) low-grade glioma trials. Interphase fusion of CEP1 and 19p12 probes detected the t(1;19). 1p/19q deletions were evaluated by fluorescence in situ hybridization. Upon culture, one oligodendroglioma contained an unbalanced 45,XX,t(1;19)(q10;p10). CEP1/19p12 fusion was observed in all metaphases and 74% of interphase nuclei. Among Mayo Clinic oligodendrogliomas, the prevalence of fusion was 81%. Among NCCTG patients, CEP1/19p12 fusion prevalence was 55%, 47%, and 0% among the oligodendrogliomas, mixed oligoastrocytomas, and astrocytomas, respectively. Ninety-one percent of NCCTG gliomas with 1p/19q deletion and 12% without 1p/19q deletion had CEP1/19p12 fusion (P < 0.001, ² test). The median overall survival (OS) for all patients was 8.1 years without fusion and 11.9 years with fusion (P = 0.003). The median OS for patients with low-grade oligodendroglioma was 9.1 years without fusion and 13.0 years with fusion (P = 0.01). Similar significant median OS differences were observed for patients with combined 1p/19q deletions. The absence of alterations was associated with a significantly shorter OS for patients who received higher doses of radiotherapy. Our results strongly suggest that a t(1;19)(q10;p10) mediates the combined 1p/19q deletion in human gliomas. Like combined 1p/19q deletion, the 1;19 translocation is associated with superior OS and progression-free survival in low-grade glioma patients. (Cancer Res 2006; 66(20): 9852-61)

This article has been cited by other articles:

				D. Mahajan and R. A. Prayson Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases Am J Clin Pathol, July 1, 2009; 132(1): 118 - 124. [Abstract] [Full Text] [PDF]

				J. E. C. Bromberg and M. J. van den Bent Oligodendrogliomas: Molecular Biology and Treatment Oncologist, February 1, 2009; 14(2): 155 - 163. [Abstract] [Full Text] [PDF]

				F. Ducray, E. Criniere, A. Idbaih, K. Mokhtari, Y. Marie, S. Paris, S. Navarro, F. Laigle-Donadey, C. Dehais, J. Thillet, et al. {alpha}-Internexin expression identifies 1p19q codeleted gliomas Neurology, January 13, 2009; 72(2): 156 - 161. [Abstract] [Full Text] [PDF]

				M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro-oncol, January 1, 2009; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]

				S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al. Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337. [Abstract] [Full Text] [PDF]

				A. Idbaih, E. Criniere, Y. Marie, A. Rousseau, K. Mokhtari, M. Kujas, Y. El Houfi, C. Carpentier, S. Paris, B. Boisselier, et al. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas Neuro-oncol, August 1, 2008; 10(4): 540 - 547. [Abstract] [Full Text] [PDF]

				P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]

				W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF]

				R. Brown, M. Zlatescu, A. Sijben, G. Roldan, J. Easaw, P. Forsyth, I. Parney, R. Sevick, E. Yan, D. Demetrick, et al. The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma Clin. Cancer Res., April 15, 2008; 14(8): 2357 - 2362. [Abstract] [Full Text] [PDF]

				F. G. Davis, B. S. Malmer, K. Aldape, J. S. Barnholtz-Sloan, M. L. Bondy, T. Brannstrom, J. M. Bruner, P. C. Burger, V. P. Collins, P. D. Inskip, et al. Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 484 - 489. [Abstract] [Full Text] [PDF]

				G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, A. Idbaih, F. Ducray, J. Thillet, K. Hoang-Xuan, et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri Neurology, February 19, 2008; 70(8): 590 - 595. [Abstract] [Full Text] [PDF]

				The German Glioma Network, M. Weller, H. Berger, C. Hartmann, J. Schramm, M. Westphal, M. Simon, R. Goldbrunner, D. Krex, J. P. Steinbach, et al. Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? Clin. Cancer Res., December 1, 2007; 13(23): 6933 - 6937. [Abstract] [Full Text] [PDF]

				J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm Central Nervous System Tumors Mayo Clin. Proc., October 1, 2007; 82(10): 1271 - 1286. [Abstract] [Full Text] [PDF]

				D. Schiff, P. D. Brown, and C. Giannini Outcome in adult low-grade glioma: The impact of prognostic factors and treatment Neurology, September 25, 2007; 69(13): 1366 - 1373. [Abstract] [Full Text] [PDF]

				C. Hong, K. S. Moorefield, P. Jun, K. D. Aldape, S. Kharbanda, H. S. Phillips, and J. F. Costello Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth PNAS, June 26, 2007; 104(26): 10974 - 10979. [Abstract] [Full Text] [PDF]

				P. Y. Wen and L. M. DeAngelis Chemotherapy for low-grade gliomas: Emerging consensus on its benefits Neurology, May 22, 2007; 68(21): 1762 - 1763. [Full Text] [PDF]